Nanjing Pharmacare has established long-term strategic partnerships with a number of internationally renowned pharmaceutical leading companies, and its agents cover multiple therapeutic areas such as cardiovascular, central nervous system, anti-tumor, and respiratory systems.
Pharmacare focuses on studying the dynamics of the Chinese pharmaceutical market and discovering the needs of customers. Committed to providing domestic customers with imported APIs of good quality, new varieties and scarce markets, helping domestic customers to obtain the first generic drugs license, seizing the market, and improving competitiveness, and the APIs we provide will be registered in the United States and Europe at the same time. It is beneficial for domestic partners to register formulation products in the United States and Europe.Mrs.Lisa, +86-25-86622972, lisa@fmkpharm.com
Mr.Jerry, +86-25-86622645, jerry.yao@fmkpharm.com
Download all product descriptions
NO. | Product Name | USDMF | NMPA | Whether can support to formulation technical transfer | Indications |
---|---|---|---|---|---|
1 | Dabigatran Etexilate Mesylate | Y | FDA:27037 A EU:√ CDE: Y20190000613 I | Y | Cardiovascular |
2 | Carboprost Trometamol | Y | Y20200000103 | Drainage contraction | |
3 | Lurasidone Hydrochloride | Y | Y20190000477、2020 planning | Y | Antipsychotic |
4 | Vildagliptin | Diabetes | |||
5 | Rosuvastatin Calcium | Y | Y20190000940 | Y | Anti-hyperlipidemia |
6 | Empagliflozin | Y | 2020 planning | Diabetes | |
7 | Avanafil | Y | 2020 planning | pulmonary hypertension | |
8 | Linagliptin | Y | 2020 planning | Y | Diabetes |
9 | Posaconazole | Y | 2020 planning | Antifungal | |
10 | Rivaroxaban | Y | 2020 planning | Y | Cardiovascular |
11 | Duloxetine Hydrochloride | Y | 2020 planning | Antidepressant | |
12 | Aripiprazole | Y | 2020 planning | Anti-epileptic | |
13 | Eslicarbazepine Acetate | Y | Anti-epileptic | ||
14 | Pioglitazone Hydrochloride | Y | Y20170001510、Y20190021512 | Diabetes |